Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 14/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 0.60 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30505247 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL188505 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| Hydrochloric Acid SCHEMBL30080174 | 0.99 | MAP2K1 (0.97) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL30022894 | 0.94 | MAP2K1 (0.88) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL28884401 | 0.94 | MAP2K1 (0.88) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29413395 | 0.89 | MAP2K1 (0.80) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL1488448 | 0.89 | MAP2K1 (0.80) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29781341 | 0.88 | MAP2K1 (0.78) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL24195834 | 0.88 | MAP2K1 (0.78) | MAP2K1MAP2K2PIM1CAMK2BIDO1 | |
| SCHEMBL4851710 | 0.88 | MAP2K1 (0.78) | MAP2K1MAP2K2PIM1CAMK2BIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622947-A1 | ENAMINE N-OXIDE TOOLS FOR TARGET IDENTIFICATION APPLICATIONS | Dana-Farber Cancer Institute, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025054260-A1 | INHIBITORS OF MEK KINASE | KINNATE BIOPHARMA INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| EP-4086250-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2024112754-A1 | ENAMINE N-OXIDE TOOLS FOR TARGET IDENTIFICATION APPLICATIONS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-4375273-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| CN-116472292-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| EP-4157888-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | Cullgen (Shanghai), Inc. (CN) | 2023-04-05 | — | — | EP | disclosed |
| US-20230100458-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-30 | — | — | US | disclosed |
| CN-115803024-A | Composition comprising arylamide derivatives | 中外制药株式会社 | 2023-03-14 | — | — | CN | disclosed |
| EP-4086250-A2 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | The Regents Of The University Of Michigan (US) | 2022-11-09 | — | — | EP | disclosed |
| CN-109563088-B | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K and therapeutic uses | 密歇根大学董事会 | 2022-10-11 | — | — | CN | disclosed |
| US-11465978-B2 | Anthranilic amides and the use thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2022-10-11 | — | — | US | disclosed |
| CN-114929669-A | Arylamide derivatives having antitumor activity | 中外制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| EP-3481822-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021263188-A9 | LIVE CELL ENGAGEMENT ASSAY | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-06-09 | — | — | WO | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| WO-2022018875-A1 | ARYLAMIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CELL PROLIFERATION DISEASES | 中外製薬株式会社 | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100458-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | API5, MAPKAPK5, MAP3K5 | MAP2K1 315/4885MAP2K2 144/4885PIM1 1919/4885 |
| US-11465978-B2 | Anthranilic amides and the use thereof | MAPKAPK5, MAP3K5, API5 | MAP2K1 301/4885MAP2K2 149/4885PIM1 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.